Response to Daily 10 Mg Alfuzosin Predicts Acute Urinary Retention and Benign Prostatic Hyperplasia Related Surgery in Men With Lower Urinary Tract Symptoms

Journal of Urology

Volumn 176, Issue 3, 2006, Pages 1051-1056

  Emberton, Mark ^a   Lukacs, Bertrand ^b   Matzkin, Haim ^c   Alcaraz, Antonio ^d   Elhilali, Mostafa ^e   Vallancien, Guy ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HÔPITAL TENON   (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e HOSPITAL CLÍNIC   (Spain)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

adrenergic alpha antagonists; alfuzosin; prostate; prostatic hyperplasia; urination disorders

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONSERVATIVE TREATMENT; DISEASE COURSE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE HYPERTROPHY; RELAPSE; RISK ASSESSMENT; TREATMENT RESPONSE; URINARY TRACT DISEASE; URINE RETENTION;

ACUTE DISEASE; ADRENERGIC ALPHA-ANTAGONISTS; AGED; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUINAZOLINES; URINARY RETENTION; URINATION DISORDERS;

EID: 33746535067     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.04.044     Document Type: Article

References (18)

1. Emberton M., Andriole G.L., De La Rosette J., Djavan B., Hoefner K., Navarrette R.V., et al. Benign prostatic hyperplasia. a progressive disease of aging men. Urology 61 (2003) 267
2. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A., et al. Natural history of prostatism. risk factors for acute urinary retention. J Urol 158 (1997) 481
3. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A., et al. Treatment for benign prostatic hyperplasia among community dwelling men. the Olmsted County study of urinary symptoms and health status. J Urol 162 (1999) 1301
4. Kolman C., Girman C.J., Jacobsen S.J., and Lieber M.M. Distribution of post-void residual urine in randomly selected men. J Urol 161 (1999) 122
5. Meigs J.B., Barry M.J., Giovannucci E., Rimm E.B., Stampfer M.J., and Kawachi I. Incidence rates and risk factors for acute urinary retention. the health professionals followup study. J Urol 162 (1999) 376
6. Roehrborn C.G., McConnell J.D., Lieber M.M., Kaplan S., Geller J., Mallek G.H., et al. Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 53 (1999) 473
7. Roehrborn C.G., and MTOPS Research Group. Baseline measures as predictors of clinical progression of benign prostatic hyperplasia. Eur Urol 3 suppl (2004) 88 abstract 344
8. Emberton M., Elhilali M., Matzkin H., Harving N., van Moorselaar J., Hartung R., et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 66 (2005) 316
9. Roehrborn C.G. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia. a randomized, placebo-controlled trial. Urology 58 (2001) 953
10. Roehrborn C.G., van Kerrebroeck P., and Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia. a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92 (2003) 257
11. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 95 (2005) 1006
12. Hartung R., Matzkin H., Alcaraz A., Emberton M., Harving N., van Moorselaar J., et al. Age, comorbidity and antihypertensive comedication do not affect cardiovascular tolerability of alfuzosin 10 mg once daily. J Urol 175 (2006) 624
13. AUA guideline on management of benign prostatic hyperplasia: (2003). Chapter 1: diagnosis and treatment recommendation. Guidelines Committee. J Urol 170 (2003) 530
14. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole G.L., Dixon C.M., Kuzek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
15. Wyllie M.G., and Andersson K.E. Ejaculatory dysfunction. why all alpha-blockers are not equal. BJU Int 92 (2003) 875
16. Wyllie M.G., and Andersson K.E. Why all alpha-blockers are not equal with respect to sexual function. J Urol 173 suppl (2005) 444 abstract 1641
17. Rouquier L., Claustre Y., and Benavides J. α1-Adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum. a microdialysis study. Eur J Pharmacol 261 (1994) 59
18. Giuliano F., Bernabe J., Laurin M., Benoît G., Droupy S., Alexandre L., et al. Tamsulosin impairs bulbospongiosus muscle (BS) contractions induced by central injection of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in anaesthetised rats while alfuzosin does not. J Urol 173 suppl (2005) 391 abstract 1444